Hemogenyx Pharmaceuticals Share Discussion Threads

[purple11] 20/9/2019 20:10

all about net yesr for me gl

[purple11] 12/9/2019 07:20

Fantastic ppl working for us.top drawer.gl

[purple11] 12/9/2019 07:20

Fantastic ppl working for us.top drawer.gl

[purple11] 06/9/2019 23:29

Not rocket science

Yet

Nfx

[purple11] 31/8/2019 02:57

The Longer the Base the Higher to Space.gl

[volsung] 29/8/2019 23:05

I shudda bought IDE but thems the breaks

[purple11] 29/8/2019 23:05

In May 2018, Hemogenyx struck a development agreement with an unnamed multinational biopharmaceutical company regarding its CDX antibody (CDX Ab), the Group’s lead asset. The partner has initiated preliminary discussions regarding a potential licensing deal. If the partner chooses to in-license the CDX Ab product candidate, we expect the partner would finance and manage the development of the platform through clinical trials, which would significantly reduce the capital required for commercialisation.




"should the unnamed partner license the CDX Ab product we would expect the partner topay Hemogenyx a substantial upfront payment and thenfinance and manage the rest of the development of the programme.We would also expect Hemogenyx to secure significant future milestone and royalty payments on such an agreement."


Hemogenyx operates in an area of intense focus for industry. Therefore, we compiled a peer group of ex-UK development-stage companies which operate within similar treatment areas to Hemogenyx (i.e. treatment of blood cancers or alternate therapies for bone marrow transplants). The median-market capitalisation of the peer-group is £129.1m, over 10-fold higher than that of Hemogenyx (Table 1).
We then compared Hemogenyx to several AIM or LSE standard-listed drug developers at a preclinical stage (Table 2). As is demonstrated, Hemogenyx’s current market capitalisation is half that of the peer-group median of c.£17.2m. Given that the Company has multiple assets, each with collaboration agreements, we believe that this price discrepancy is unjustified and that Hemogenyx shares consequently have considerable upside potential

[purple11] 29/8/2019 21:08

xXTiPSXHEETSXx

[purple11] 29/8/2019 20:57

BUY HOLD ADD seize the chance to build your holding and wait.

12 22 43

[purple11] 29/8/2019 20:56

relax

stocks are marked down across the board atm incase you hadn't noticed .summer doldrums and the sept swooon gl

[purple11] 18/6/2019 10:27

or IW UWILL.


BUYYE

[purple11] 18/6/2019 10:26

another time another place peter e

[purple11] 18/6/2019 10:22

ULL GET CHEAPER MAYBE MAYbEnot

buy all these xprICess

[purple11] 18/6/2019 10:19

atleeste we tried.

[purple11] 18/6/2019 10:19

DONTASKXME wHEN HOW WH OR If



YOU DECIDE.



GL AND GB

[purple11] 18/6/2019 10:18

678 ist stop





xXTiPSXHEETS

[purple11] 18/6/2019 10:17

added
gl
uspellIt rite buy pcx

[renalrod] 10/8/2018 10:16

Never trust someone who can't "right" properly on ye olde BB